Thus, the role of PD-1 and PD-L1 blockade in advanced endometrial cancers can be significant, and there have been some phase 1 and phase 2 studies done to evaluate the anti-tumor efficacy, safety, and survival analysis in this population. Here, CD274 is linked to neoplasm.